Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
P/B ratio for Sutro Biopharma, Inc. (STRO)
P/B ratio as of 2023: 1.72
According to Sutro Biopharma, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.72. At the end of 2022 the company had a P/B ratio of 1.89.
P/B ratio history for Sutro Biopharma, Inc. from 2016 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.72 |
| 2022 | 1.89 |
| 2021 | 2.72 |
| 2020 | 2.13 |
| 2019 | 2.58 |
| 2018 | 0.39 |
| 2017 | -0.98 |
| 2016 | -1.17 |